Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study
Jonathan W. Riess(University of California Davis Medical Center), David R. Gandara(University of California, Davis), Kurt A. Schalper(Yale University), Laurel Beckett(Brigham and Women's Hospital), Arta M. Monjazeb(University of California Davis Medical Center), Karen Kelly(Cancer Research Center), Michiko Shimoda(University of California, San Francisco), Guillaume Luxardi(UC Davis Health), Samantha Herbert(UC Davis Comprehensive Cancer Center), Elizabeth Moore(UC Davis Comprehensive Cancer Center), Miguel López de Rodas(Yale Cancer Center), Alexander Meerlev(UC Davis Comprehensive Cancer Center), Emanual Maverakis(University of California, Davis)
Cited by 2
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k